Gut Bacterium Link to Colon Cancer Finally Cracked
Johns Hopkins scientists find the missing link showing how Bacteroides fragilis triggers colorectal cancer using a specific protein docking point.
For nearly twenty years, a medical mystery has haunted researchers: how does a common gut bacterium actually begin its attack on the colon to trigger cancer? Now, scientists at Johns Hopkins have finally uncovered the missing link, revealing the exact mechanism that allows a specific bacterium to breach the body's defenses and promote tumor growth.
The Culprit: Bacteroides fragilis
The investigation focuses on Bacteroides fragilis, a bacterium that resides in the intestines of up to 20% of healthy individuals. While having this bacterium doesn't guarantee a cancer diagnosis, certain strains are far more dangerous than others. These specific strains produce a potent substance known as B. fragilis toxin (BFT).
BFT is known to disrupt the protective lining of the colon, sparking chronic inflammation and creating an environment where tumors can flourish. While a landmark 2009 study established the connection between this toxin and colorectal cancer, the "how" remained elusive.
The Mystery of the Docking Point
Researchers previously discovered that BFT damages a protein called E-cadherin, which acts like a cellular glue holding the colon's protective barrier together. When E-cadherin is destroyed, the barrier collapses, allowing harmful substances to seep into surrounding tissues.
However, a critical puzzle remained: BFT did not seem to attach directly to E-cadherin. Scientists suspected there was a "middleman"—a specific molecule that acted as a docking station—but years of attempts to find it had failed.
CRISPR Solves the Cold Case
To break the deadlock, a team led by the Johns Hopkins Kimmel Cancer Center, the Bloomberg~Kimmel Institute for Cancer Immunotherapy, and the Johns Hopkins University School of Medicine turned to CRISPR gene-editing technology.
Led by M.D./Ph.D. candidate Maxwell White in collaboration with Harvard Medical School, the team performed a genome-wide CRISPR screening. By systematically switching off genes in colon epithelial cells, they were able to identify the essential docking point the toxin requires to begin its assault.
The Discovery: Claudin-4
The study, published in Nature, identifies a protein called claudin-4 as the essential receptor. BFT uses claudin-4 as its entry point, attaching to it before it can go on to destroy E-cadherin and damage the intestinal lining.
A New Path to Prevention
This discovery is more than just academic; it has immediate therapeutic potential. The researchers have already developed a molecular decoy designed to intercept the BFT toxin before it can reach the claudin-4 docking point.
In laboratory tests, this strategy successfully protected mice from the harmful effects of the toxin, offering a promising new blueprint for preventing bacterial damage associated with colorectal cancer.
"Understanding how bacterial toxins work can open doors to new approaches for detection and therapy for associated diseases, including diarrhoea, colorectal cancer and bloodstream infections," stated senior author Cynthia Sears, M.D., Bloomberg~Kimmel Professor of Cancer Immunotherapy.
The research, which received partial support from the National Institutes of Health, marks a pivotal shift in how doctors might one day detect and treat toxin-driven cancers.